The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / High Cost of Rheumatoid Arthritis Medications Burdens Patients in Saudi Arabia

High Cost of Rheumatoid Arthritis Medications Burdens Patients in Saudi Arabia

March 20, 2017 • By Lina El Kibbi

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In the past 15 years, rheumatoid arthritis (RA) has posed an economic burden on patients in Saudi Arabia due to the high cost of the medications used to treat the condition. As a rheumatology consultant, I’ve observed the economic impact on patients in one clinic in a private hospital in Riyadh.

You Might Also Like
  • Factors that Influence Biologic Therapy Choices for Patients with Rheumatoid Arthritis
  • High Cost of DMARDs Could Limit Medicare Patients’ Treatment Adherence
  • ACR Advances Legislation to Increase Patients’ Access to Biologic Drugs to Treat Rheumatoid Arthritis and Other Conditions
Explore This Issue
March 2017

RA is a chronic, disabling disease with negative effects on patients’ quality of life and a disproportinate economic impact on people of working age. The impact is observed in the patient’s productivity, family and society.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

As rheumatologists, we follow the current recommendations from the European League Against Rheumatism (EULAR) and the ACR, which provide algorithms for the use of traditional disease-modifying anti-rheumatic drugs (DMARDs) and biologics. We choose medications guided by disease activity through physical examination, laboratory tests, radiological changes on X-rays and musculoskeletal ultrasonography.

As we all know, advances have been made in the treatment of RA, but the treatments place an economic burden on the patient, payers and society. The annual cost for an RA patient’s treatment at a private hospital can be estimated at approximately 60,000 SAR (Saudi Arabian Riyal) or ≈$15,979 yearly.

TABLE 1

(click for larger image)
Table 1

Biologic medications that we are using in our hospital are listed in Table 1 (above). The greatest impact of biologics is on the uninsured and certain insured cases. Here, I describe five different scenarios that patients in our clinic in a private hospital face to get their treatment.

Scenario 1: We all know that not all patients have the luxury of having medical insurance. Here, we call an uninsured Saudi or expatriate patient a cash patient, someone who will pay their own expenses, including purchasing at high cost their medications.

Scenario 2: Some patients have medical insurance, but their insurance refuses to pay for treatment because the disease is chronic, started before the begining date of the insurance policy or the patient didn’t indicate up front that they had the disease.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Scenario 3: The patient has insurance but the insurance company rejects the medication.

Scenario 4: At first, the patient will get approval from the insurance company and take their medication, but upon annual renewal, the insurance company will raise the cost of the insurance to the insured patient’s employer, cancel the policy or change the terms so that the insurance does not cover anything related to rheumatology.

Scenario 5: The patient is taking the medication, which has already been approved, but their employer changes its insurance company after a year, and the journey starts again.

The Way Forward

We need to help the RA patient by educating those in our surrounding environment to understand the impact of disease. We need to help patients find the best way to get the right management and to convince the insurance company to look at these cases from a different angle so that patients with ankylosing spondylitis, psoriatic arthritis and RA who are on a biologic can get the treatment they need.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: adalimumab, burden, Certolizumab Pegol, cost, drug, etanercept, expense, Golimumab, infliximab, Medication, Patients, Rheumatoid arthritis, rheumatology, Saudia ArabiaIssue: March 2017

You Might Also Like:
  • Factors that Influence Biologic Therapy Choices for Patients with Rheumatoid Arthritis
  • High Cost of DMARDs Could Limit Medicare Patients’ Treatment Adherence
  • ACR Advances Legislation to Increase Patients’ Access to Biologic Drugs to Treat Rheumatoid Arthritis and Other Conditions
  • Implementing Successful Care Management Programs for High-Cost Patients

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.